John Moolenaar Urges Defense Department to Add 120 Chinese Schools and Tech Labs to US Research Funding Watchlist

Top Analyst Says iPhone 18 Pro and Pro Max Lead Times Have Dropped, But Apple’s Cycle Is ‘Off to a Solid Start’

Apple iPhone Pro lead times dropped, but Deepwater Asset Management's Gene Munster still sees a solid start.

Caterpillar vs. Corning: Which Industrials Stock Is a Better Buy in 2026?

The article compares two industrial stocks: Caterpillar, a construction and mining equipment titan with record backlog and growing dividends, versus Corning, a materials science leader benefiting from AI data center demand. While Caterpillar offers proven industrial exposure with reliable income, Corning's optical communications business is growing over 30% year-over-year with ambitious revenue targets of $20B by end-2026, $30B by 2028, and $40B by 2030. The author recommends Corning for patient investors seeking exposure to AI infrastructure growth.

Apple's iPhone Order Cut Is a Fall Tradition — And So Is the Stock Rebound

Apple fell on reports of 15% iPhone 18 Pro order cuts, but Bespoke says this happens every year — and the stock recovers.

UBS Maintains Neutral on AbbVie, Raises Price Target to $275

UBS analyst Michael Yee maintains AbbVie (NYSE:ABBV) with a Neutral and raises the price target from $260 to $275.

A Stock Market Crash Is Coming By the End of 2027, According to Some Economists. Here Are 2 Stocks to Buy Before That Happens

Some economists predict a market downturn and recession by end of 2027. The article recommends two pharmaceutical stocks—AbbVie and Amgen—as defensive investments that have historically weathered downturns well due to their diversified drug portfolios, consistent revenue from chronic disease treatments, strong pipelines, and reliable dividend payments.

Guggenheim Reiterates Buy on AbbVie, Maintains $288 Price Target